Diffuse panbronchiolitis

Jump to navigation Jump to search
Diffuse panbronchiolitis
ICD-10 J21.9
ICD-9 466.1
OMIM 604809
DiseasesDB 3804

Diffuse panbronchiolitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diffuse panbronchiolitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diffuse panbronchiolitis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diffuse panbronchiolitis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diffuse panbronchiolitis

CDC on Diffuse panbronchiolitis

Diffuse panbronchiolitis in the news

Blogs on Diffuse panbronchiolitis

Directions to Hospitals Treating Diffuse panbronchiolitis

Risk calculators and risk factors for Diffuse panbronchiolitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Error creating thumbnail: File missing
A simple diagram of the respiratory system: 1. trachea, 2. pulmonary artery, 3. pulmonary vein, 4. alveolar duct, 5. alveoli, 6. cardiac notch, 7. bronchiole, 8. tertiary bronchi, 9. secondary bronchi, 10. primary bronchi, 11. larynx

Prevalence

Symptoms

Pathogenesis

Treatment

Macrolide antibiotics, such as erythromycin, clarithromycin and roxithromycin, have proven to be an effective long-term treatment for DPB.[1][2] The successful results of macrolides in DPB and similar lung diseases stems from controlling symptoms through immunomodulation (adjusting the immune response),[2] with the added benefit of low-dose requirements.[1]

With macrolide therapy in DPB, great reduction in bronchiolar inflammation and damage is achieved through suppression of not only neutrophil granulocyte proliferation, but also lymphocyte activity and obstructive mucus and sputum secretions in airways.[1] The antimicrobial and antibiotic effects of macrolides, however, are not believed to be involved in their beneficial effects toward treating DPB.[3] This is evident, as the treatment dosage is much too low to fight infection, and in DPB cases with the occurrence of macrolide-resistant pseudomonas aeruginosa, macrolide therapy still produces substantial anti-inflammatory results.[1]

Advanced cases of DPB, where severely excessive sputum production resistant to macrolides persists, additional therapy with the inhalant tiotropium has been shown to ease these symptoms and the related shortness of breath.[4]

See also

References

  1. 1.0 1.1 1.2 1.3 Keicho N, Kudoh S (2002). "Diffuse panbronchiolitis: role of macrolides in therapy". Am J Respir Med. 1 (2): 119–131. PMID 14720066.
  2. 2.0 2.1 Lopez-Boado YS, Rubin BK (2008). "Macrolides as immunomodulatory medications for the therapy of chronic lung diseases". Curr Opin Pharmacol. Epub ahead of print. PMID 18339582.
  3. Schultz MJ (2004). "Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis". J Antimicrob Chemother. 54 (1): 21–28. PMID 15190022.
  4. Saito Y, Azuma A, Morimoto T, Fujita K, Abe S, Motegi T, Usuki J, Kudoh S (2008). "Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy". Intern Med. 47 (7): 585–591. PMID 18379141.


Template:Respiratory pathology

Template:Jb1

Template:WikiDoc Sources